Fauci & Collins Cashed In on Covid: Records Show 58 NIH Royalty Payments Worth $325M. Newly discovered records have exposed the staggering profits that were reaped in the form of royalty checks on the back of the Covid pandemic.
The records show that the former heads of the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID) massively cashed in from the pandemic.
Former NIH Director Dr. Francis Collins and former NIAID Director Dr. Tony Fauci reportedly received 58 royalty payments between them from companies to license their COVID-19 shots for public use.
The injections were also developed by private pharmaceutical companies using American taxpayer money.
Fauci and Collins both heavily profited through royalties from the continuing payments that arrived in their bank accounts throughout the “pandemic.”
Transparency watchdog OpenTheBooks has published more than 1,500 pages of unredacted records this week.
The documents show which companies paid Fauci and Collins for their inventions.
The records were obtained through a mostly successful probe using the Freedom of Information Act (FOIA).
The NIH fought tooth and nail to stop the FOIA requests from being fulfilled.
However, OpenTheBooks was ultimately able to procure most of what it sought.
All in all, there were 56,000 transactions amounting to more than $325 million.
The only thing we do not know is the individual amounts for each payment and its corresponding licenses, which are not listed in the records.
Fauci personally received 37 payments from three companies between 2010 and 2021.
Those payments include 15 from Santa Cruz Biotechnology, which manufactures products for medical research including antibodies.
Santa Cruz Biotechnology made the fifth-most payments in the royalty database.
Fauci also took in 14 payments from Ancell Corp., which produces immunology tolls, as well as eight payments from Chiron Corp., which was acquired by Novartis in 2006.
“Novartis has received $17 million in NIH contract payments and $15 million in NIH grants since the acquisition,” Just the News reports.
“Fauci’s NIAID contracted with Chiron in 2004 to help develop an avian influenza vaccine.
“He was the highest-paid federal employee when Fauci retired at year’s end, with a $480,000 salary in 2022.”
As for Collins, the former NIH director who stepped down to serve as Democrat President Joe Biden’s Covid “czar,” collected 21 payments from four different companies between 2010 and 2018.
The genetic research firm GeneDx accounted for 12 of them, having received $5 million in federal contract payments, mostly from the NIH, since 2008.
“Four payments to Collins came from Quest Diagnostics’ Specialty Laboratories, which provides biological testing services; four from Ionis Pharmaceuticals, originally named ISIS, known for RNA-targeted therapeutics; and one from Progeria Research Foundation, a nonprofit specializing in research for the congenital disorder,” explains Just the News.
OpenTheBooks says it needs the names and license numbers for each payment, which the NIH conveniently redacted before a court ordered that this information be made public.
The organization says it requires this missing information in order to scrutinize the records “for potential conflicts of interest or public health risks.”
The information could help to provide further evidence of whether or not Fauci lied under oath during a hearing last year.
Fauci told Sen. Rand Paul (R-KY) that he “doubts” he received any royalties from any entity that received money from the NIAID.
Fauci was overseeing NIAID at the time.
According to an Associated Press investigation, Fauci was already confirmed to have received more than $45,000 in royalties nearly two decades earlier, when he was also NIAID director, for an experimental AIDS treatment funded by NIH.
OpenTheBooks said later studies showed it had “zero efficacy” and that Fauci “never provided proof” of his claim that he’d donate the royalties to charity.
Fauci & Collins Cashed In on Covid: Records Show 58 NIH Royalty Payments Worth $325M